RBC Santarus at outperform

Santarus Inc. was rated at outperform, speculative risk, with a $10 price target, by RBC Capital Markets analyst Douglas Miehm on news the company plans to hire 150 sales reps in the fourth quarter through a contract sales organization. The larger sales force makes Santarus more attractive from a partnering/in-licensing point of view, according to Miehm. Shares of the San Diego-based pharmaceutical company were down 4 cents, or 0.55%, at $8.18. (Nasdaq: SNTS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.